Analysed PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) News Sources
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07-05-2026
yahoo.com
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
15-05-2026
yahoo.com
Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation
19-05-2026
yahoo.com
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
20-05-2026
yahoo.com
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
21-05-2026
yahoo.com
What is the current price of PALVELLA THERAPEUTICS INC (PVLA:NASDAQ)?
The current price of PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) is $116.26.
PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) absolute price change since previous trading day?
The absolute price change of PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) since the previous trading day is $-1.33.
PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) percentage price change since previous trading day?
The percentage price change of PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) since the previous trading day is -1.131%.
What is the most recent average sentiment score for PALVELLA THERAPEUTICS INC (PVLA:NASDAQ)?
The most recent average sentiment score for PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for PALVELLA THERAPEUTICS INC (PVLA:NASDAQ)?
The most recent sentiment for PALVELLA THERAPEUTICS INC (PVLA:NASDAQ) is .
SEC-8K** Filing Available For PALVELLA THERAPEUTICS INC (PVLA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.